Bayer's €2 Billion Hybrid Issue Lifts Outstanding Notes to €6.55 Billion as Stivarga Sale and Missouri Ruling Set the Next Tests

Bayer raises €2B in hybrid bonds, brings in Apollo and KKR for its contraceptive unit, and awaits a Missouri ruling on its $7.25B Roundup settlement.

Bayer has spent the past several weeks assembling a financial toolkit that leans on outside capital, asset sales and fresh debt — a three-pronged effort to whittle down obligations and free up cash for the businesses it intends to keep. The market has taken notice: the DAX-listed stock closed Friday at €50.20, up 36% since the start of the year, a run that has pushed the shares well above their 200-day moving average of €42.80.

At the center of the balance-sheet overhaul sits a €2 billion hybrid bond placement. The transaction lifts Bayer's total outstanding hybrid notes to €6.55 billion, instruments that straddle the line between equity and debt and give the company accounting breathing room while locking in fixed coupon obligations. The two tranches carry 30-year maturities and coupons of 5.75% and 6.25% respectively — rigid costs that will weigh on future earnings unless operating cash flow keeps pace.

Apollo and KKR Anchor a Contraceptive Vehicle

A second pillar took shape on September 16, when Apollo and KKR agreed to provide a €3 billion capital solution and take equity stakes in a newly created entity holding Bayer's long-acting reversible contraceptive business. Bayer retains both a majority interest and operational control of the unit. For shareholders, the structure represents a shift in how the company manages its resources — one that brings in external funding without carving out entire divisions, keeping established cash flows under Bayer's operational grip.

The arrangement does carry longer-term tensions. Apollo and KKR will expect attractive returns from the joint vehicle, and if growth in the contraceptive segment falls short of expectations, the complex corporate structure could end up burdening the balance sheet rather than relieving it.

Divestments Add Direct Liquidity

Bayer is also shedding older pharmaceutical assets. Grünenthal has agreed to acquire the cancer drug Stivarga for up to €375 million, a deal subject to regulatory clearances and expected to close by the end of 2026 or early 2027. Proceeds from such sales deliver immediate liquidity and let the group sharpen its focus on higher-margin therapeutic areas, while sparing Bayer future internal resource commitments on mature products.

On the agricultural side, the company is deploying venture capital through its Leaps by Bayer unit. A participation in the Series A round of biotechnology firm Robigo targets genetically optimized crop protection solutions, with Bayer eyeing a market launch in 2028.

Smaller operational adjustments are running in parallel. On Wednesday, Bayer introduced a mono-material blister packaging for its stomach remedy Talcid on the German market, with a rollout to additional European markets planned for 2026 and 2027.

Missouri Courtroom Holds the Key

Tied tightly to the balance-sheet outlook is Bayer's legal reckoning in the United States. Roughly two weeks ago, the company and its Monsanto subsidiary pressed a Missouri court to approve a proposed $7.25 billion settlement covering tens of thousands of Roundup herbicide claims. According to Reuters, no immediate ruling followed the hearing. Since that proceeding, the stock has gained 3.0%.

Should the settlement deliver the legal calm Bayer is seeking, a paralyzing uncertainty would lift. The pharmaceutical business, meanwhile, is supplying fresh clinical momentum: more than a month ago, the U.S. Food and Drug Administration approved Kerendia for the treatment of adult patients with chronic kidney disease associated with type 1 diabetes — the first new approval in that specific indication in more than three decades, according to the company.

What Could Still Go Wrong

The risk of a setback remains real despite recent progress. The pivotal danger lies in a delay or rejection of the proposed agreement by the Missouri judge. If judicial approval of the multibillion-dollar settlement fails, litigation exposure would swell anew, tying up fresh equity and rattling institutional investors once more.

The refinanced liabilities add their own drag. The hybrid coupons are inflexible, and if the hoped-for operating gains in the agricultural division fail to materialize, those fixed payments would narrow Bayer's financial room for maneuver considerably. Management is under pressure to translate the incoming funds into measurable balance-sheet improvement — and every quarterly report from here will be judged first and foremost on the pace of debt reduction.

Two concrete dates now frame the investment case. The judge's decision on the $7.25 billion U.S. settlement will define the legal perimeter. On the operational front, the planned completion of the Stivarga sale to Grünenthal — targeted for late 2026 or early 2027, pending regulatory approval — marks the next milestone. How Bayer performs against both will determine whether the restructuring holds.